The Thessaloniki Eye Study (TES) is a major population based study of glaucoma and age-related macular degeneration (AMD) conducted from 1999 to 2004, with interesting findings in the Greek population and related impact in international literature. Important information was revealed during this study, including open angle glaucoma and AMD prevalence as well as association of blood pressure status with optic disc structure. Undiagnosed glaucoma and glaucoma types including pseudoexfoliative glaucoma have been studied through TES. Data analysis is ongoing and the findings are subject of recent and upcoming publications.
There is also participation in major European projects. The Eureye study was a multicenter epidemiological study which offered important information about AMD prevalence and risk factors in the European population.
One of the major ongoing studies is the GlaucoGENE project, a multicenter genetic epidemiology study of glaucoma under the auspices of the European Glaucoma Society. The Laboratory is involved not only as a participating center but also has the organizational and administrative duties for the project.
Recently, the Laboratory was succesful in obtaining a grant to realize the Thessaloniki Eye Study Incidence Study. This will give the opportunity to investigate the 10-year incidence of glaucoma and AMD in the original Thessaloniki Eye Study cohort.
Clinical Research
Currently running clinical trials:

  • 2 clinical trials on glaucoma
  • 1 clinical trial on pediatric/juvenile glaucoma
  • 1 clinical trial on diabetic macular edema

More specifically, currently running clinical trials are the following:

  • CCT-IOP: Central Corneal Thickness and 24h Fluctuation of Intraocular Pressure (Clinical NCT00941525, 2009-ongoing).
  • Circadian Ocular Perfusion Pressure and Ocular Blood Flow (Clinical NCT00800540, 2009-ongoing).
  • A prosperctive, non-interventional longitudinal cohort study to evaluate the long-term safety of Xalatan treatment in pediatric populations (multicenter study, Clinical NCT01265719, 2011-ongoing.)
  • "RETAIN" study. A multicenter trial in patients diabetic macular edema (clinical NCT01171976, 2011-ongoing).

Other clinical trials conducted at the LaRCAO:

  • 31/04/2003 – 31/08/2004: A twelve-month, multicenter, randomized, double-masked study to evaluate the efficacy and safety of once-daily instillation of Travoprost 0.004% / Timolol 0.5% and Latanoprost 0.005% / Timolol 0.5% eye drops in subjects with open-angle glaucoma or ocular hypertension”. Protocol No: C-02-28, Project No: 31-5518. Alcon Research. 
  • 31/1/2002 – 31/12/2003: A six-week, double masked parallel group, primary therapy study of the safety and efficacy of Travoprost 0.004% compared to Latanoprost 0.005% followed by a six-week open label treatment on Travoprost 0.004% in patients with open-angle glaucoma or ocular hypertension”. Project No: Al-6221 RD315202), Protocol No: Co 01-14. Alcon Research.